病例报告:一个患有兰伯特-伊顿肌痛综合征的患者成功地用Efgartigimod治疗
Lizhu Han1,2, Jili Shen3, Jie Wei3
1Department of Neurology, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, People's Republic of China.
International medical case reports journal
|December 3, 2025
概括
治疗efgartigimod显著改善了兰伯特-伊顿肌综合征 (LEMS) 患者的情况.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 兰伯特-伊顿肌综合征 (LEMS) 是一种罕见的自身免疫性疾病,影响神经肌肉结节.
- LEMS通常与特定的癌症有关,其特征是对电压通道 (VGCC) 的抗体.
研究的目的:
- 报告首次使用efgartigimod在一个被诊断为兰伯特-伊顿肌综合征的患者身上.
- 评估efgartigimod在管理LEMS症状中的临床疗效和安全性.
主要方法:
- 一名73岁的小细胞肺癌和被诊断为LEMS的男性接受了efgartigimod (10毫克/公斤每周) 的治疗.
- 监测了临床症状,神经电生理学发现和血清抗体水平 (VGCC,SOX-1,IgG).
- 在efgartigimod治疗之前进行了皮质类固醇治疗,最初的改善有限.
主要成果:
- 在efgartigimod治疗三周后,观察到LEMS临床表现的显著改善.
- 在服用efgartigimod后,VGCC抗体和总IgG的血清水平下降.
- 患者在说话,吞,抬头和肢体力量方面经历了改善.
结论:
- 在这位LEMS患者中,efgartigimod显示出了实质性的临床益处.
- 这一案例表明efgartigimod可能是兰伯特-伊顿肌综合征的一种有前途的治疗选择.
- 需要进一步的临床试验来证实efgartigimod在LEMS治疗中的有效性和作用.
更多相关视频
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
4.4K
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
2.9K
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...